Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Executive Summary

FDA considering public statement reflecting its view that biosimilars not deemed interchangeable will not be substituted at pharmacy, but the extent such a statement would limit payer-driven practice remains in question.

Advertisement

Related Content

Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Humira Biosimilar Interchangeability: The Race Begins
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilar Prescribing Decisions May Depend Upon Disease State
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar Interchangeability Requirements Pushed At Inflectra Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118771

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel